Glow Blend

The Glow Blend combines BPC-157, TB-500 (thymosin β4), and GHK-Cu, co-lyophilized for studies that pair tissue-repair profiles with dermal and extracellular-matrix research. Because it is a mixture rather than a single molecule, it carries no single CAS number or formula; its research context is best read alongside the dedicated BPC-157, TB-500, and GHK-Cu listings.

Each component is studied for a distinct but complementary process: BPC-157 for soft-tissue and vascular repair, TB-500/Tβ4 for cell migration and regeneration, and GHK-Cu for collagen and extracellular-matrix remodeling in skin. [1][3][5] This rationale is mechanistic and drawn from the separate single-agent literatures; controlled studies establishing a specific advantage of the three-way combination are limited, and none support human use.

BPC-157 is a stable gastric pentadecapeptide studied in preclinical models of musculoskeletal soft-tissue and dermal wound healing, with a recurring proposed mechanism of promoting angiogenesis. [1][2]

TB-500 corresponds to thymosin β4, the major actin-sequestering peptide in mammalian cells, studied as a multifunctional regenerative peptide tied to cell migration and to endothelial/vascular remodeling. [3][4]

GHK-Cu is a naturally occurring copper-binding tripeptide studied in skin remodeling, collagen and glycosaminoglycan synthesis, [5] and as a broad modulator of tissue-repair gene-expression programmes. [6]

All three components are research compounds supported predominantly by animal and in-vitro evidence. This blend is supplied strictly for in-vitro and laboratory research by qualified professionals — it is not formulated, dosed, or authorised for use in humans or animals, and nothing here is a therapeutic or cosmetic-efficacy claim.